The apelin receptor, therefore, presents a highly tractable drug target for cardiovascular disorders characterised by high blood pressure and a failing heart, such as pulmonary arterial hypertension (PAH) (36–41). This evidence concerns the gene APLNR and pulmonary arterial hypertension.